Lenograstim

ApprovedProtein / enzyme

Sanofi

Lenograstim is one of 216 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

215

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Germ Cell TumorActive, not recruiting

Prostate CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

GrowthActive, not recruiting

NeutropeniaApproved

Active, not recruiting

Germ Cell TumorPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 2/Phase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

GrowthPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Lenograstim

Sanofi

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Prednisone/prednisolone

Roche

Preclinical

3 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—8

Naropin

FFresenius Kabi Oncology Ltd.

Statin

1 10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Maintenance Therapy1 trial

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Completed·UUniversity of Ulm·Phase 2·NCT01180322·277 enrolled

Prostate Cancer1 trial

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Terminated·BBarts & The London NHS Trust·Phase 2/3·NCT01907009·29 enrolled

Germ Cell Tumor1 trial

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

Unknown status·UUniversity of Southampton·Phase 1/2·NCT00551122·23 enrolled

Neutropenia1 trial

A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen

Completed· Sanofi logo

Sanofi·Phase 4·NCT01107756·403 enrolled

Efficacy1 trial

Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)

Unknown status·DDERSHENG SUN·N/A·NCT03498248·155 enrolled

6 more indications

Acute Myeloid Leukemia1 trial

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·PPETHEMA Foundation·Phase 3·NCT02319135·289 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Multiple Myeloma1 trial

Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Unknown status·UUniversity of Pisa·Phase 3·NCT00932217·180 enrolled

Growth1 trial

Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)

Recruiting·CCellProthera·Phase 1·NCT05594433·40 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

Lymphoproliferative Disease1 trial

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Completed·WWiSP Wissenschaftlicher Service Pharma GmbH·Phase 2/3·NCT01085058·169 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lenograstim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lenograstim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lenograstim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: Sanofi

Lenograstim

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Maintenance Therapy1 trial

Prostate Cancer1 trial

Germ Cell Tumor1 trial

Neutropenia1 trial

Efficacy1 trial

Acute Myeloid Leukemia1 trial

Advanced Stage1 trial

Multiple Myeloma1 trial

Growth1 trial

Diffuse Large B-Cell Lymphoma1 trial

Lymphoproliferative Disease1 trial

References

Drug Info

Quick Facts

Related News